Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis. (2nd January 2019)

• Record Type: Journal Article
• Authors: Fabiani, Claudia; Sota, Jurgen; Vitale, Antonio; Emmi, Giacomo; Vannozzi, Lorenzo; Bacherini, Daniela; Lopalco, Giuseppe; Guerriero, Silvana; Venerito, Vincenzo; Orlando, Ida; Franceschini, Rossella; Fusco, Fiorella; Frediani, Bruno; Galeazzi, Mauro; Iannone, Florenzo; Tosi, Gian Marco; Cantarini, Luca
• Is Part Of: Ocular immunology and inflammation. Volume 27:Number 1(2019)
• Page Start: 34
• Page End: 39
• Publication Date: 2019-01-02
• Subjects: Behçet's disease -- drug retention rate -- infliximab -- treatment -- uveitis; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2017.1391297
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose : To evaluate the 10-year drug retention rate of infliximab (IFX) in Behçet's disease (BD)-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on drug survival and differences according to the lines of biologic treatment. Methods : Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves. Results : Forty patients (70 eyes) were eligible for analysis. The drug retention rates at 12-, 24-, 60- and 120-month follow-up were 89.03%, 86.16%, 75.66% and 47.11% respectively. No differences were identified according to the use of concomitant DMARDs ( p = 0.20), while a statistically significant difference was observed in relation to the different lines of IFX treatment ( p = 0.014). Visual acuity improved from baseline to the last follow-up visit ( p = 0.047) and a corticosteroid-sparing effect was observed ( p < 0.0001). Conclusions : IFX retention rate in BD-uveitis is excellent and is not affected by concomitant DMARDs.